Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
NiKang Completes First Cohort Dosing in NKT3964 Phase 1 CDK2 Degrader Study
Details : NKT3964, a first-in-class, highly potent and selective, orally bioavailable CDK2 degrader, which is being evaluated for the treatment of solid tumors.
Product Name : NKT3964
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 10, 2025
Lead Product(s) : NKT2152,Atezolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
NiKang Doses First Patient in Phase 1b/2 Study of NKT2152 for Hepatocellular Carcinoma
Details : NKT2152, a highly potent, selective & orally bioavailable small molecule HIF2α inhibitor, in combination with standard-of-care in the first-line treatment of patients with advanced or metastatic HCC.
Product Name : NKT2152
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 21, 2025
Lead Product(s) : NKT2152,Atezolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
NiKang Doses First Patient in Phase 1/1b Study of NKT3447, a Selective CDK2 Inhibitor
Details : NKT3447 is an oral, selective inhibitor of CDK2 which reduces cyclin E expression. It is being evaluated for the treatment of patients with cancers driven by cyclin E amplification or overexpression.
Product Name : NKT3447
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 15, 2024
Lead Product(s) : NKT2152,Atezolizumab
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : F. Hoffmann-La Roche
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims to evaluate NKT2152, a small molecule that inhibits hypoxia inducible factor 2α (HIF2α), in combination with standard-of-care Tecentriq (atezolizumab) and Avastin (bevacizumab) in first-line treatment of unresectable/advanced hep...
Product Name : NKT2152
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 12, 2023
Lead Product(s) : NKT2152,Atezolizumab
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : F. Hoffmann-La Roche
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : NKT2152
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The anti-tumor effect observed in several xenograft models suggests NKT2152, a HIF2α inhibitor, may have broader activity in other solid tumors beyond ccRCC that lack a VHL gene deficiency.
Product Name : NKT2152
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 04, 2022
Lead Product(s) : NKT2152
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NKT2152
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Hansoh Pharma
Deal Size : $218.0 million
Deal Type : Collaboration
Details : Under the terms of the agreement, Hansoh will be responsible for all the development costs for NKT2152 in Greater China and will receive the exclusive rights to develop and commercialize NKT2152 in the region.
Product Name : NKT2152
Product Type : Other Small Molecule
Upfront Cash : $15.0 million
March 05, 2022
Lead Product(s) : NKT2152
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Hansoh Pharma
Deal Size : $218.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Cormorant Asset Management
Deal Size : $200.0 million
Deal Type : Series C Financing
NiKang Therapeutics Announces Completion of $200 Million Series C Financing
Details : Proceeds will be used to advance the company’s lead drug candidates into the clinic, expand the pipeline and fund internal drug discovery programs.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 26, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Cormorant Asset Management
Deal Size : $200.0 million
Deal Type : Series C Financing
Lead Product(s) : NKT-1992
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Hansoh Pharma
Deal Size : $100.0 million
Deal Type : Collaboration
Details : Under the terms of the collaboration, Hansoh Pharma will be responsible for leading development and commercialization of NKT-1992 in Greater China.
Product Name : NKT-1992
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 23, 2020
Lead Product(s) : NKT-1992
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Hansoh Pharma
Deal Size : $100.0 million
Deal Type : Collaboration